New Brand Drug Pipeline
| Medication (Brand name) | Drug Class | Therapeutic Use | Status Update |
|---|---|---|---|
| Celecoxib Oral Liquid (Elyxyb™) | NSAID | Migraine Headache Treatment | Launch pending. Approved May 5, 2020. |
| Benzhydrocodone HCl/ Acetaminophen (Apadaz™) |
Opioid Analgesic – Immediate Release |
Pain | Launch pending. Approved February 23, 2018. |
| Buprenorphine Depot Injection (Brixadi™) |
Opioid Agonist | Treatment of Opioid Addiction |
FDA declined to review December 2020. |
| Celecoxib/Tramadol | NSAID/Opioid Agonist | Pain | FDA review pending. |
| Oxycodone Aximris XR™ | Opioid Analgesic – Extended Release |
Pain | FDA review pending. |
| Ansofaxine | Antidepressant | Major Depressive Disorder |
FDA review pending. |
| Naloxone Injection (Zimhi™) | Opioid Antagonist | Opioid Overdose | FDA review pending. |
Generic Pipeline
| Medication (Brand name) | Drug Class | Therapeutic Use | Status Update |
|---|---|---|---|
| Pregabalin Extended Release (Lyrica® CR) | Anticonvulsant | Neuropathic Pain | Patent exclusivity expires April 2021. |
| Dabigatran (Pradaxa®) | Anticoagulant | Treatment/Prophylaxis of Deep Vein Thrombosis | First patent set to expire December 2021. |
| Apixaban (Eliquis®) | Anticoagulant | Treatment/Prophylaxis of Deep Vein Thrombosis | Generics approved December 23, 2019, but settlements expected to delay launch for at least a few years. |
| Naloxone HCl (Narcan®) Nasal Spray |
Opioid Antagonist | Opioid Overdose | Launch pending. Generic approved April 19, 2019. |
Available in the Last 12 Months
| Medication (Brand name) | Drug Class | Therapeutic Use | Status Update |
|---|---|---|---|
| Oliceridine (Olinvyk™) Injection | Opioid Agonist | Pain | November 2020 |
| Tramadol Oral Solution (Qdolo™) | Opioid Agonist | Pain | October 2020 |
| Rimegepant (Nurtec™ ODT) | CGRP Antagonist | Migraine Headache Treatment | March 2020 |
| Ubrogepant (Ubrelvy™) | CGRP Antagonist | Migraine Headache Treatment | March 2020 |
Newly Available Generics
| Medication (Brand name) | Drug Class | Therapeutic Use | Status Update |
|---|---|---|---|
| Meloxicam (Vivlodex®) | NSAID | Pain | December 2020 |
| Emtricitabine/Tenofovir (Truvada®) |
Antiretroviral | HIV Post-Exposure Prophylaxis |
Generic anticipated late 2020. |
| Albuterol Sulfate (Proventil® HFA) | Inhaled Bronchodilator | Asthma | April 2020 |
| Naproxen/Esomeprazole (Vimovo®) | NSAID/GI Protectant | Pain/Stomach Ulcer Prophylaxis | February 2020 |
| Albuterol Sulfate (ProAir® HFA) | Inhaled Bronchodilator | Asthma | February 2020 |
Discontinuations & Withdrawals
| Medication (Brand name) | Drug Class | Therapeutic Use | Status Update |
|---|---|---|---|
| Naloxone HCl (Evzio®) | Opioid Antagonist | Opioid Overdose | The manufacturer made a business decision to discontinue in September 2020. |
| Albuterol Sulfate | Inhaled Bronchodilator | Asthma | Perrigo Company recalled all lots of its generic inhaler in September 2020. |
| Ranitidine (Zantac®) | H-2 Receptor Antagonist | Heartburn/Stomach Ulcer Prophylaxis | FDA asked all manufacturers to remove product from the market on April 1, 2020. |